EUVIMEDEUVIMED entdecken
Klinische Studie (Phase II)Randomisierte kontrollierte StudieMultizentrische StudieOpen Access · CC BY-NC 4.0

Efficacy and safety of etrasimod in alopecia areata: A multicentre, randomized, double‐blind, placebo‐controlled, Phase 2 study

B King iD, N Mesinkovska, M Senna iD, X Luo, J Minkiewicz, A Selfridge

Journal of the European Academy of Dermatology and Venereology · 2025-06 · 39 (6) · 1174-1184

DOI: 10.1111/jdv.20605 ↗

Kurz gefasst

Klinische Studie (Phase II) in der Zeitschrift Journal of the European Academy of Dermatology and Venereology, online erschienen am 27.03.2025. Verfasst von B King und 5 weiteren Autor:innen. Beteiligte Einrichtung: Dermatology Physicians of Connecticut, Fairfield, Connecticut, USA. Hauptthemen laut MEDLINE: Alopecia Areata. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Pfizer Inc, Pfizer.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Etrasimod, an oral, selective sphingosine 1‐phosphate 1, 4 and 5 receptor modulator approved for the treatment of ulcerative colitis, has been studied in immune‐mediated inflammatory diseases, including alopecia areata (AA).

Objectives

To evaluate the efficacy and safety of etrasimod in adults with moderate to severe AA.

Methods

This Phase 2, randomized, double‐blind, placebo‐controlled trial included patients (aged ≥18 years) with moderate to severe AA, defined as a Severity of Alopecia Tool (SALT) score of ≥25. Patients were sequentially enrolled into two cohorts. Cohort 1 included patients (SALT score of ≥50) randomized 2:1 to etrasimod 2 mg or placebo. Cohort 2 included patients (SALT score ≥25 to

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Alopecia AreataAdultFemaleHumansMaleMiddle AgedYoung AdultDouble-Blind MethodTreatment OutcomeAcetatesIndoles

Substanzen

etrasimodAcetatesIndoles

Autor:innen und Institutionen

  • Dermatology Physicians of Connecticut, Fairfield, Connecticut, USA.
  • Department of Dermatology and Dermatopathology, UCI School of Medicine, Irvine, California, USA.
  • Lahey Hospital and Medical Center, Burlington, Massachusetts, USA.
  • Pfizer China R&D Center, Shanghai, China.
  • Pfizer Inc, New York, New York, USA.

ORCID-Profile: B King, M Senna

Förderung

  • Pfizer Inc
  • Pfizer

Zitieren

APA

King, B., Mesinkovska, N., Senna, M., Luo, X., Minkiewicz, J., & Selfridge, A. (2025). Efficacy and safety of etrasimod in alopecia areata: A multicentre, randomized, double‐blind, placebo‐controlled, Phase 2 study. Journal of the European Academy of Dermatology and Venereology, 39(6), 1174-1184. https://doi.org/10.1111/jdv.20605

Vancouver

King B, Mesinkovska N, Senna M, Luo X, Minkiewicz J, Selfridge A. Efficacy and safety of etrasimod in alopecia areata: A multicentre, randomized, double‐blind, placebo‐controlled, Phase 2 study. Journal of the European Academy of Dermatology and Venereology. 2025;39(6):1174-1184. doi:10.1111/jdv.20605

BibTeX
@article{King2025,
  author = {King, B and Mesinkovska, N and Senna, M and Luo, X and Minkiewicz, J and Selfridge, A},
  title = {Efficacy and safety of etrasimod in alopecia areata: A multicentre, randomized, double‐blind, placebo‐controlled, Phase 2 study},
  journal = {Journal of the European Academy of Dermatology and Venereology},
  year = {2025},
  volume = {39},
  number = {6},
  pages = {1174--1184},
  doi = {10.1111/jdv.20605}
}
Kostenlos starten →